Litcius/Paper detail

Invasive Pneumococcal Disease in High-risk Children: A 10-Year Retrospective Study

Jacqui van Warmerdam, Aaron Campigotto, Ari Bitnun, Georgina MacDougall, Melanie Kirby‐Allen, Blake C. Papsin, Allison McGeer, Upton Allen, Shaun K. Morris

2022The Pediatric Infectious Disease Journal18 citationsDOI

Abstract

BACKGROUND: Despite the availability of conjugate pneumococcal vaccines, children with high-risk conditions remain vulnerable to invasive pneumococcal disease (IPD). This study sought to describe IPD prevalence, vaccination and outcomes among high-risk children. METHODS: We used International Classification of Disease10 discharge and microbiology codes to identify patients hospitalized for IPD at a large pediatric hospital from January 1, 2009, to December 31, 2018. Patients were considered high-risk if they had: primary immunodeficiency, asplenia, transplant, active malignancy, sickle cell disease, cochlear implant, nephrotic syndrome, chronic lung disease, cerebrospinal fluid leak, HIV or used immunosuppressive therapy. RESULTS: In total 94 high-risk patients were hospitalized for IPD. The most common high-risk conditions included malignancy (n = 33, 35%), solid-organ or bone marrow transplant (n = 17, 18%) and sickle cell disease (n = 14, 15%). Bacteremia was the most common presentation (n = 81, 86%) followed by pneumonia (n = 23, 25%) and meningitis (n = 9, 10%). No deaths occurred. Of 66 patients with known pneumococcal vaccination status, 15 (23%) were unvaccinated, and 51 (77%) received at least one dose of a pneumococcal vaccine; 20 received all four recommended pneumococcal conjugate vaccine (PCV) doses. Only three children received PPSV23. Of 20 children with no or partial (<3 doses) immunization, 70% (14) of IPD episodes were due to vaccine-preventable serotypes. Of 66 known IPD serotypes, 17% (n = 11) were covered by PCV13, 39% (n = 26) were covered by PPSV23 and 39% (n = 26) were nonvaccine serotype. CONCLUSIONS: Despite the availability of effective pneumococcal vaccines, IPD persists among children with high-risk conditions. Improving PCV13 and PPSV23 vaccination could significantly reduce IPD; most episodes were due to vaccine-preventable serotypes in incompletely immunized patients.

Topics & Concepts

MedicinePneumococcal conjugate vaccinePediatricsMeningitisPneumococcal vaccineVaccinationInternal medicinePneumoniaStreptococcus pneumoniaeImmunologyAntibioticsBiologyMicrobiologyPneumonia and Respiratory InfectionsRespiratory viral infections researchInfluenza Virus Research Studies
Invasive Pneumococcal Disease in High-risk Children: A 10-Year Retrospective Study | Litcius